Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter
Shockwave Medical, Inc. · Decision date Feb 12, 2021
What did the FDA approve?
The FDA database entry records an approval decision dated February 12, 2021, for the Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter. The stated indication is lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting.
The entry lists Shockwave Medical, Inc. as the applicant, with product code QMG under the cardiovascular specialty. No supplement type or supplement reason is provided, so the record does not identify this as a change to a prior PMA. The source statement describes the reported intended use; it does not independently establish safety or clinical effectiveness.
FDA approval order statement
Approval for the Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter. The Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 IVL Coronary Catheter is indicated for lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 12, 2021
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P200039
- Regulatory pathway
- Premarket approval application
- Applicant
- Shockwave Medical, Inc.
- Product code
- QMG
- Decision code
- APPR
- Decision date
- Feb 12, 2021
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Shockwave intravascular lithotripsy system.
- Applicant
- Shockwave Medical, Inc.
- Product code
- QMG
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P200039 received
Application receipt date recorded by FDA.
P200039 · FDA decision
APPR
P200039/S025 · Related supplement
SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH SHOCKWAVE C2/C2+ CORONARY IVL CATHETER
Timeline entries are records held by MedtechLedger for P200039. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200039
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Shockwave Medical, Inc. | PMA supplement | Sep 11, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Shockwave Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5403 Betsy Ross Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P200039
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records